Compare Illinois Tool Works Inc. (ITW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs TG Therapeutics Inc — how do they compare? Illinois Tool Works Inc. trades at $293.28 (market cap $83.49B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Illinois Tool Works Inc. is far larger — about 10.9× TG Therapeutics Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ITW | TGTX | |
|---|---|---|
Market Cap | $83.49B | $7.64B |
Sector | Industrials | Health |
52-Week High | $299.60 | $59.06 |
52-Week Low | $241.07 | $26.94 |
Enterprise Value | $92.34B | $7.84B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $292.54, down 0.67% on the day, with a bullish technical signal and strong fundamentals including a 19.39% net income margin and consistent earnings beats. Recent news highlights a 7% dividend increase and a $6 billion share repurchase program, reflecting management confidence. The stock is near key support at $290 with resistance at $300.
Outlook is positive due to robust profitability and shareholder returns, but risks include high valuation multiples and debt levels. Analyst consensus is mixed with a $314.25 price target, suggesting moderate upside potential amid cautious sentiment from some institutional sellers.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
